Regadenoson Impurity 37 NEW

Regadenoson Impurity 37

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

• 
  

• Product Information

• Product Number: R013037

• English Name: Regadenoson Impurity 37

• English Alias: diethyl 1,1'-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purine-2,6-diyl)bis(1H-pyrazole-4-carboxylate)

• CAS Number: None

• Molecular Formula: C₂₂H₂₄N₈O₈

• Molecular Weight: 528.47

• Advantages

• As Impurity 37 of Regadenoson, this compound has the following advantages:
• 
  

• Well-defined with distinct polyfunctional features: Contains purine core, 2,6-bis(1H-pyrazole-4-carboxylate ethyl) substitutions, and 9-((2R,3R,4S,5R)-tetrahydrofuranosyl) (with 3,4-dihydroxy and 5-hydroxymethyl). Unlike regadenoson (purine drug with amino/hydroxy substitutions), its pyrazole aromaticity, ester hydrophobicity, and sugar polyhydroxyl polarity create significant differences, enabling precise differentiation via HPLC/ion-exchange chromatography as a specific marker;

• High stability and traceability: Rigid purine/pyrazole structures and stability of ester/glycosidic bonds ensure neutral-condition stability. As a byproduct from incomplete purine disubstitution in regadenoson synthesis, it directly reflects substitution selectivity, improving process tracing accuracy;

• High detection sensitivity: Purine-pyrazole conjugation shows strong UV absorption (250-280nm), combined with m/z 529 [M+H]⁺ enabling ppb-level analysis via LC-MS, compatible with purine heterocyclic impurity systems.

• Applications

• Pharmaceutical quality control: Used as an impurity reference standard to quantify Regadenoson Impurity 37 in APIs, ensuring residual disubstituted byproducts meet quality standards;

• Synthesis optimization: Optimizing purine 2,6-substitution conditions (reagent ratio) by monitoring impurity levels to enhance target specificity and reduce bis-pyrazole carboxylate impurities;

• Intermediate purity assessment: Evaluating purity of key purine-sugar intermediates in regadenoson synthesis to support subsequent functional group modification.

• Background Description

• Regadenoson is a vasodilator containing purine and tetrahydrofuranosyl groups, synthesized via selective purine substitution and glycosylation. Non-specific disubstitution of purine 2,6-positions with pyrazole carboxylate ethyl (instead of target monosubstitution) may generate diethyl 1,1'-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purine-2,6-diyl)bis(1H-pyrazole-4-carboxylate) derivatives like Regadenoson Impurity 37. Altering purine electron distribution, its residues may affect adenosine receptor binding, making control critical for efficacy and safety.

• Research Status

• Current research focuses on:
• 
  

• Analytical method validation: Developing HPLC assays with C18 columns for separation, achieving 0.1 ppb detection limits;

• Substitution kinetics: Studying impurity formation under varying reagent concentrations to clarify purine disubstitution pathways;

• Control strategies: Using selective reagents or stepwise substitution to keep impurity levels below 0.1% and enhance API purity;

• Structural confirmation: Using ¹H/¹³C-NMR and polarimetry to verify sugar chirality and substitution positions, distinguishing from regadenoson for authoritative identification.

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com